125 related articles for article (PubMed ID: 21317541)
1. Nasal delivery of P-gp substrates to the brain through the nose-brain pathway.
Shingaki T; Hidalgo IJ; Furubayashi T; Sakane T; Katsumi H; Yamamoto A; Yamashita S
Drug Metab Pharmacokinet; 2011 Jun; 26(3):248-55. PubMed ID: 21317541
[TBL] [Abstract][Full Text] [Related]
2. Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil.
Gramatté T; Oertel R
Clin Pharmacol Ther; 1999 Sep; 66(3):239-45. PubMed ID: 10511059
[TBL] [Abstract][Full Text] [Related]
3. P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound.
Spahn-Langguth H; Baktir G; Radschuweit A; Okyar A; Terhaag B; Ader P; Hanafy A; Langguth P
Int J Clin Pharmacol Ther; 1998 Jan; 36(1):16-24. PubMed ID: 9476144
[TBL] [Abstract][Full Text] [Related]
4. The transnasal delivery of 5-fluorouracil to the rat brain is enhanced by acetazolamide (the inhibitor of the secretion of cerebrospinal fluid).
Shingaki T; Hidalgo IJ; Furubayashi T; Katsumi H; Sakane T; Yamamoto A; Yamashita S
Int J Pharm; 2009 Jul; 377(1-2):85-91. PubMed ID: 19446619
[TBL] [Abstract][Full Text] [Related]
5. Role of p-glycoprotein in region-specific gastrointestinal absorption of talinolol in rats.
Kagan L; Dreifinger T; Mager DE; Hoffman A
Drug Metab Dispos; 2010 Sep; 38(9):1560-6. PubMed ID: 20538723
[TBL] [Abstract][Full Text] [Related]
6. Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans.
Schwarz UI; Gramatté T; Krappweis J; Berndt A; Oertel R; von Richter O; Kirch W
Clin Pharmacol Ther; 1999 Mar; 65(3):283-90. PubMed ID: 10096260
[TBL] [Abstract][Full Text] [Related]
7. Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data.
Hsiao P; Sasongko L; Link JM; Mankoff DA; Muzi M; Collier AC; Unadkat JD
J Pharmacol Exp Ther; 2006 May; 317(2):704-10. PubMed ID: 16415090
[TBL] [Abstract][Full Text] [Related]
8. Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates.
El Ela AA; Härtter S; Schmitt U; Hiemke C; Spahn-Langguth H; Langguth P
J Pharm Pharmacol; 2004 Aug; 56(8):967-75. PubMed ID: 15285840
[TBL] [Abstract][Full Text] [Related]
9. Administration of drugs known to inhibit P-glycoprotein increases brain bilirubin and alters the regional distribution of bilirubin in rat brain.
Hankø E; Tommarello S; Watchko JF; Hansen TW
Pediatr Res; 2003 Oct; 54(4):441-5. PubMed ID: 12904601
[TBL] [Abstract][Full Text] [Related]
10. Effect of continuous silymarin administration on oral talinolol pharmacokinetics in healthy volunteers.
Han Y; Guo D; Chen Y; Tan ZR; Zhou HH
Xenobiotica; 2009 Sep; 39(9):694-9. PubMed ID: 19555315
[TBL] [Abstract][Full Text] [Related]
11. Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans.
Gramatté T; Oertel R; Terhaag B; Kirch W
Clin Pharmacol Ther; 1996 May; 59(5):541-9. PubMed ID: 8646825
[TBL] [Abstract][Full Text] [Related]
12. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction.
Westphal K; Weinbrenner A; Zschiesche M; Franke G; Knoke M; Oertel R; Fritz P; von Richter O; Warzok R; Hachenberg T; Kauffmann HM; Schrenk D; Terhaag B; Kroemer HK; Siegmund W
Clin Pharmacol Ther; 2000 Oct; 68(4):345-55. PubMed ID: 11061574
[TBL] [Abstract][Full Text] [Related]
13. In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect.
Tubic M; Wagner D; Spahn-Langguth H; Bolger MB; Langguth P
Pharm Res; 2006 Aug; 23(8):1712-20. PubMed ID: 16832615
[TBL] [Abstract][Full Text] [Related]
14. Circadian variations in exsorptive transport: in situ intestinal perfusion data and in vivo relevance.
Okyar A; Dressler C; Hanafy A; Baktir G; Lemmer B; Spahn-Langguth H
Chronobiol Int; 2012 May; 29(4):443-53. PubMed ID: 22489638
[TBL] [Abstract][Full Text] [Related]
15. Transnasal delivery of 5-fluorouracil to the brain in the rat.
Sakane T; Yamashita S; Yata N; Sezaki H
J Drug Target; 1999; 7(3):233-40. PubMed ID: 10680979
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of brain-targeting for the nasal delivery of estradiol by the microdialysis method.
Wang X; He H; Leng W; Tang X
Int J Pharm; 2006 Jul; 317(1):40-6. PubMed ID: 16631329
[TBL] [Abstract][Full Text] [Related]
17. A kinetic evaluation of the absorption, efflux, and metabolism of verapamil in the autoperfused rat jejunum.
Johnson BM; Chen W; Borchardt RT; Charman WN; Porter CJ
J Pharmacol Exp Ther; 2003 Apr; 305(1):151-8. PubMed ID: 12649363
[TBL] [Abstract][Full Text] [Related]
18. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier.
Hendrikse NH; de Vries EG; Eriks-Fluks L; van der Graaf WT; Hospers GA; Willemsen AT; Vaalburg W; Franssen EJ
Cancer Res; 1999 May; 59(10):2411-6. PubMed ID: 10344751
[TBL] [Abstract][Full Text] [Related]
19. Estimation of the unbound brain concentration of P-glycoprotein substrates or nonsubstrates by a serial cerebrospinal fluid sampling technique in rats.
Mariappan TT; Kurawattimath V; Gautam SS; Kulkarni CP; Kallem R; Taskar KS; Marathe PH; Mandlekar S
Mol Pharm; 2014 Feb; 11(2):477-85. PubMed ID: 24380373
[TBL] [Abstract][Full Text] [Related]
20. Brain distribution of ribavirin after intranasal administration.
Colombo G; Lorenzini L; Zironi E; Galligioni V; Sonvico F; Balducci AG; Pagliuca G; Giuliani A; Calzà L; Scagliarini A
Antiviral Res; 2011 Dec; 92(3):408-14. PubMed ID: 22001322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
